CN101679477A - 17β-氰基-18a-同型-19-去甲-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物 - Google Patents

17β-氰基-18a-同型-19-去甲-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物 Download PDF

Info

Publication number
CN101679477A
CN101679477A CN200880020040A CN200880020040A CN101679477A CN 101679477 A CN101679477 A CN 101679477A CN 200880020040 A CN200880020040 A CN 200880020040A CN 200880020040 A CN200880020040 A CN 200880020040A CN 101679477 A CN101679477 A CN 101679477A
Authority
CN
China
Prior art keywords
cyano
homo
androst
methylene
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880020040A
Other languages
English (en)
Chinese (zh)
Inventor
J·库恩克
J·许布纳
R·博尔曼
T·弗伦策尔
U·克拉尔
F·门格斯
S·林
S·博登
H-P·穆恩
K·普雷莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of CN101679477A publication Critical patent/CN101679477A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880020040A 2007-06-12 2008-06-04 17β-氰基-18a-同型-19-去甲-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物 Pending CN101679477A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007027636.4 2007-06-12
DE102007027636A DE102007027636A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
PCT/EP2008/004428 WO2008151745A1 (de) 2007-06-12 2008-06-04 17beta-cyano-18a-homo-19-nor-androst-4-en-derivat, dessen verwendung und das derivat enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
CN101679477A true CN101679477A (zh) 2010-03-24

Family

ID=38858372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880020040A Pending CN101679477A (zh) 2007-06-12 2008-06-04 17β-氰基-18a-同型-19-去甲-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物

Country Status (21)

Country Link
US (1) US20090048218A1 (enExample)
EP (1) EP2178899B1 (enExample)
JP (1) JP2010529152A (enExample)
KR (1) KR20100017780A (enExample)
CN (1) CN101679477A (enExample)
AR (1) AR066970A1 (enExample)
AU (1) AU2008261277A1 (enExample)
BR (1) BRPI0813455A2 (enExample)
CA (1) CA2689563A1 (enExample)
CL (1) CL2008001721A1 (enExample)
DE (1) DE102007027636A1 (enExample)
ES (1) ES2397879T3 (enExample)
IL (1) IL202300A0 (enExample)
MX (1) MX2009013626A (enExample)
PA (1) PA8784201A1 (enExample)
PE (1) PE20090312A1 (enExample)
RU (1) RU2010100334A (enExample)
TW (1) TW200906846A (enExample)
UY (1) UY31145A1 (enExample)
WO (1) WO2008151745A1 (enExample)
ZA (1) ZA201000185B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
WO2012116290A2 (en) * 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
PT2935307T (pt) 2012-12-18 2018-07-31 Univ Washington Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SI2986624T1 (sl) 2013-04-17 2020-10-30 Sage Therapeutics, Inc. 19-nor nevroaktivni steroidi za metode zdravljenja
TR201901745T4 (tr) 2013-04-17 2019-03-21 Sage Therapeutics Inc 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20230170816A (ko) 2014-10-16 2023-12-19 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
PT3206493T (pt) 2014-10-16 2020-08-03 Sage Therapeutics Inc Composições e métodos para tratamento de transtornos do snc
JP6893173B2 (ja) 2014-11-27 2021-06-23 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
HUE054092T2 (hu) 2015-01-26 2021-08-30 Sage Therapeutics Inc Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
NZ790226A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
IL32699A (en) * 1968-07-30 1973-06-29 American Home Prod 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them
FR2081561B1 (enExample) * 1970-03-03 1973-04-06 Roussel Uclaf
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (enExample) 1971-06-01 1974-08-23 Roussel Uclaf
US3994937A (en) * 1972-02-11 1976-11-30 Schering Aktiengesellschaft 15α,16α-Methylene-4-estren-17β-ols
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
UY31145A1 (es) 2009-01-30
BRPI0813455A2 (pt) 2014-12-23
PE20090312A1 (es) 2009-04-09
CL2008001721A1 (es) 2008-12-19
RU2010100334A (ru) 2011-07-20
CA2689563A1 (en) 2008-12-18
PA8784201A1 (es) 2009-01-23
WO2008151745A1 (de) 2008-12-18
MX2009013626A (es) 2010-01-20
ZA201000185B (en) 2011-03-30
DE102007027636A1 (de) 2008-12-18
IL202300A0 (en) 2010-06-30
TW200906846A (en) 2009-02-16
ES2397879T3 (es) 2013-03-12
EP2178899A1 (de) 2010-04-28
AR066970A1 (es) 2009-09-23
EP2178899B1 (de) 2012-10-24
US20090048218A1 (en) 2009-02-19
KR20100017780A (ko) 2010-02-16
AU2008261277A1 (en) 2008-12-18
JP2010529152A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
CN101679477A (zh) 17β-氰基-18a-同型-19-去甲-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物
CN101511857B (zh) 18-甲基-19-去甲雄-4-烯-17,17-螺醚(18-甲基-19-去甲-20-螺-4-烯-3-酮)及包含它的药物制品
CN101128476A (zh) 18-甲基-19-去甲-17-孕-4-烯-21,17-内酯化合物、以及包含该化合物的药物组合物
CN101679478A (zh) 17β-氰基-19-去甲-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物
AU2008266526A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
CN101679479A (zh) 17β-氰基-19-雄甾-4-烯衍生物、其用途以及含有该衍生物的药物
CN101918427B (zh) 15,16-亚甲基-17-(1’-丙烯基)-17-3’-环氧雌-4-烯-3-酮衍生物、其用途及包含所述衍生物的药品
CN101910192B (zh) 具有15α,16α-亚甲基和饱和的17,17-螺内酯环的19-去甲甾类衍生物、其应用以及包含这些衍生物的药物
JP5600069B2 (ja) １７−（１’−プロペニル）−１７−３’−オキシドエストラ−４−エン−３−オン誘導体、その使用及び当該誘導体を含む医薬品
CN101910190A (zh) 17-羟基-19-去甲-21-羧酸类固醇γ-内酯衍生物、其用途及包含所述衍生物的药品
HK1141536A (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative
HK1141535A (en) 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE
HK1141537A (en) 17β-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE
TW201029656A (en) Use of 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives for parenteral administration
TW201026719A (en) Use of 17β-cyano-19-nor-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-19-nor-androst-4-ene derivatives for parenteral administration
HK1133659B (en) 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one) and pharmaceutical preparations containing the same
TW201026718A (en) Use of 17β-cyano-19-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-19-androst-4-ene derivatives for parenteral administration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141536

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100324

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1141536

Country of ref document: HK